Zabana, YamileMarin-Jimenez, IgnacioRodriguez-Lago, IagoVera, IsabelMartin-Arranz, Maria DoloresGuerra, IvanGisbert, Javier PMesonero, FranciscoBenitez, OlgaTaxonera, CarlosPonferrada-Diaz, AngelPiqueras, MartaLucendo, Alfredo JCaballol, BertaMañosa, MiriamMartinez-Montiel, PilarBosca-Watts, MaiaGordillo, JordiBujanda, LuisManceñido, NoemiMartinez-Perez, TeresaLopez, AliciaRodriguez-Gutierrez, CristinaGarcia-Lopez, SantiagoVega, PabloRivero, MontserratMelcarne, LuigiCalvo, MariaIborra, MarisaBarreiro de-Acosta, ManuelSicilia, BeatrizBarrio, JesusPerez, Jose LazaroBusquets, DavidPerez-Martinez, IsabelNavarro-Llavat, MerceHernandez, VicentArguelles-Arias, FedericoRamirez Esteso, FernandoMeijide, SusanaRamos, LauraGomollon, FernandoMuñoz, FernandoSuris, Gerardde Zarate, Jone OrtizHuguet, Jose MariaLlao, JordinaGarcia-Sepulcre, Mariana FeSierra, MonicaDura, MiguelEstrecha, SandraFuentes Coronel, AnaHinojosa, EstherOlivan, LorenzoIglesias, EvaGutierrez, AnaVarela, PilarRull, NuriaGilabert, PauHernandez-Camba, AlejandroBrotons, AliciaGinard, DanielSese, EvaCarpio, DanielAceituno, MontserratCabriada, Jose LuisGonzalez-Lama, YagoJimenez, LauraChaparro, MariaLopez-San Roman, AntonioAlba, CristinaPlaza-Santos, RocioMena, RaquelTamarit-Sebastian, SonsolesRicart, ElenaCalafat, MargalidaOlivares, SonsolesNavarro, PabloBertoletti, FedericoAlonso-Galan, HoracioPajares, RamonOlcina, PabloManzano, PamelaDomenech, EugeniEsteve, Maria2023-05-032023-05-032022-01-06Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, et al. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. J Clin Med. 2022 Jan 14;11(2):4212077-0383http://hdl.handle.net/10668/21235We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19SARS-CoV-2Inflammatory bowel diseaseInflammatory bowel diseasesHospitalizationSpainIncidenceCOVID-19Risk factorsImmunosuppression therapyWorking conditionsIntensive care unitsCommunicable disease controlResearch article35054116open accessCondiciones de trabajoControl de enfermedades transmisiblesEnfermedades inflamatorias del intestinoFactores de riesgoHospitalizaciónTerapia de inmunosupresiónUnidades de cuidados intensivos10.3390/jcm11020421PMC8781643https://www.mdpi.com/2077-0383/11/2/421/pdf?version=1642173441https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781643/pdf